Experimental HCV Drugs
Experimental HCV Drugs
Promising Proof-of-concept Data for Hepatitis C NS5A Inhibitor PPI-668
- Details
- Category: HCV Treatment
- Published on Tuesday, 03 July 2012 00:00
- Written by Press Release
Presidio Pharmaceuticals' experimental hepatitis C virus (HCV) NS5A Inhibitor PPI-668 demonstrated potent antiviral activity and good tolerability in a Phase 1b proof-of-concept study of genotype 1 patients, the company reported last week.
Idenix Announces Promising Data for Hepatitis C Drugs IDX184 and IDX719
- Details
- Category: HCV Treatment
- Published on Friday, 29 June 2012 00:00
- Written by Press Release
Interim findings from a Phase 2b study show that 8 out of 9 genotype 1 chronic hepatitis C patients treated with Idenix Pharmaceuticals' experimental HCV polymerase inhibitor IDX184 with continued pegylated interferon/ribavirin through week 24 had undetectable viral load 4 weeks after competing therapy. Another trial found that the NS5A inhibitor IDX719 has activity against all HCV genotypes.
EASL 2012: Telaprevir 100% Effective for IL28B CC, Adding VX-222 Overcomes Unfavorable Genes
- Details
- Category: HCV Treatment
- Published on Wednesday, 23 May 2012 00:00
- Written by Liz Highleyman
Adding telaprevir (Incivek) to pegylated interferon and ribavirin cured all hepatitis C patients with the favorable IL28B gene pattern, researchers reported at the 47th International Liver Congress (EASL 2012) last month in Barcelona. Another study found that adding the experimental HCV polymerase inhibitor VX-222 raised cure rates even for those with unfavorable IL28B patterns.
New HCV Protease Inhibitor ACH-2684 Looks Good in Phase 1 Study
- Details
- Category: HCV Treatment
- Published on Friday, 08 June 2012 00:00
- Written by Achillion Pharmaceuticals
Achillion's next-generation hepatitis C virus (HCV) protease inhibitor ACH-2684 appeared safe and reduced HCV viral load by up to 4.16 log after 3 days of monotherapy in a Phase 1 of healthy volunteers and people with genotype 1 chronic hepatitis C, the company reported last month.
EASL 2012: MicroRNA Miravirsen Looks Safe and Effective for Genotype 1 Hepatitis C
- Details
- Category: HCV Treatment
- Published on Friday, 04 May 2012 00:00
- Written by Liz Highleyman
Miravirsen, the first microRNA therapy for hepatitis C, was well-tolerated and demonstrated prolonged antiviral activity lasting past the end of dosing in a proof-of-concept study of previously untreated HCV genotype 1 patients presented at the 47th International Liver Congress (EASL 2012) last month in Barcelona.
More Articles...
- EASL 2012: BI 201335 + BI 207127 + Ribavirin Shows Good Efficacy, Including Hepatitis C Patients with Cirrhosis
- EASL 2012: Promising Findings for Therapeutic Hepatitis C Vaccine TG4040
- EASL 2012: Boceprevir a Useful Option for Patients Who Did Not Respond to Earlier Hepatitis C Therapy
- EASL 2012: Abbott Interferon-Free HCV Combinations Show Early Promise for Untreated Patients
Web Design and Development by